hrp0086p1-p205 | Diabetes P1 | ESPE2016

Are We Screening Appropriate Age Group for Early Diagnosis of Cystic Fibrosis Related Diabetes in UK?

Gangadharan Arundoss , Berry Claire , Watling Ruth , Kerr Sue , Southern Kevin , Senniappan Senthil

Background: Nutrition plays a pivotal role in long-term survival in cystic fibrosis (CF). Early insulin treatment for glucose intolerance promotes anabolism and stabilises lung function. However there is a variation in cystic fibrosis related diabetes (CFRD) screening across centres (recommended age for start of CFRD screening varies between 10 and 12 years as per CF trust, CFF & ISPAD guidelines).Aims: To assess if early screening of glycaemic statu...

hrp0094fc4.4 | Diabetes | ESPE2021

Effect of newer CFTR modulator therapy on glycaemic control in adolescents with CFRD

Park Julie , Walsh Anna , Kerr Sue , Woodland Clare , Southward Suzanne , Deakin Mark , Thursfield Rebecca , Senniappan Senthil ,

Background: Cystic fibrosis related diabetes (CFRD) affects 40-50% of adults with Cystic Fibrosis (CF) and significantly decreases pulmonary function and affects life expectancy. Previous data highlighted that CFRD may be preventable or curable with the use of CFTR modulators, namely Ivakaftor. Kaftrio (Ivakaftor, tezacaftor and elexacaftor) has recently been licensed for use in CF. To our knowledge, its effect on glucose regulation in children and young peopl...